We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Sidmap Provides Metabolic Phenotyping Services

Sidmap Provides Metabolic Phenotyping Services

Sidmap Provides Metabolic Phenotyping Services

Sidmap Provides Metabolic Phenotyping Services

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Sidmap Provides Metabolic Phenotyping Services "

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Sidmap has announced the signing of agreements with investigators and researchers at Harvard Medical School's Joslin Diabetes Center and the University of Utah to use its isotope-based metabolic phenotyping services.

Mary-Elizabeth Patti, M.D., of the Joslin Diabetes Center at Harvard Medical School, engaged Sidmap to conduct a series of profiles to determine the metabolic perturbations of a diabetes model currently under investigation.

"The early information provided by Sidmap has been extremely revealing. The results were provided promptly and I expect to continue working with Dr. Boros and his team in the future," Dr. Patti said.

Don McClain, Ph.D., of the University of Utah, is using Sidmap's metabolic phenotyping services to evaluate an in vivo model for type II diabetes.

"The work Drs. Boros and Lee are doing is extremely exciting and we are expecting some unique insights from the metabolic profiles Sidmap is providing," said Dr. McClain.

"We are extremely pleased that these prestigious academic institutions have chosen SIDMAP as their metabolic solutions provider," said David Manheim, Sidmap's Vice President of Operations and General Counsel.

He adds, "We continue to work with pharmaceutical and biotech companies as well as academic institutions which have embraced our technology as a useful tool to enhance their research and drug development efforts. Our pipeline is robust and should continue to grow as more people learn about the dynamic biochemical information we provide."